A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection.
Phase of Trial: Phase II
Latest Information Update: 23 May 2014
At a glance
- Drugs LTX 109 (Primary)
- Indications Gram-positive infections; Skin infections
- Focus Adverse reactions
- Sponsors Lytix Biopharma
- 27 Apr 2012 Planned number of patients changed from 24 to 35 as reported by European Clinical Trials Database record.
- 15 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2010 Actual initiation date (September 2010), official title, lead investigators identified as reported by ClinicalTrials.gov.